|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | |
| A61K 39/395 | |||
| A61P 35/00 |
| (11) | Number of the document | 3066128 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14803287.3 |
| Date of filing the European patent application | 2014-11-05 | |
| (97) | Date of publication of the European application | 2016-09-14 |
| (45) | Date of publication and mention of the grant of the patent | 2018-10-31 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/064153 |
| Date | 2014-11-05 |
| (87) | Number | WO 2015/069785 |
| Date | 2015-05-14 |
| (30) | Number | Date | Country code |
| 201361900775 P | 2013-11-06 | US |
| (72) |
ANDRE, Pascale, FR
BLERY, Mathieu, FR
BONNAFOUS, Cecile, FR
GUPTA, Ashok, K., US
SALTER-CID, Luisa, M., US
ROBBINS, Michael Darron, US
|
| (73) |
Innate Pharma,
117, Avenue de Luminy, 13009 Marseille,
FR
Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, US |
| (54) | COMBINATION OF ANTI-KIR AND ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMA |
| COMBINATION OF ANTI-KIR AND ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMA |